The client’s pathologist must provide the cytogenetics report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, blood or bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), and molecular tests as medically necessary.
The client’s pathologist must provide the flow cytometry report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
The client’s pathologist must provide the morphology report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
Includes COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
Includes COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
The THxID® BRAF Mutation Analysis assay is for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin embedded (FFPE) melanoma tissue. It is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with dabrafenib, and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib.
THXID® is a registered trademark of bioMerieux.
There are key genes that are recurrently mutated in various human cancers. Genomic DNA is isolated from bone marrow, aspirates, peripheral blood or formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the ABL1, ABL2, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, ATRX, AXL, B2M, BAP1, BCL2, BCL2L11, BCL6, BCOR, BIRC3, BRAF, BRCA1, BRCA2, BTK, CALR, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD33, CD79A, CD79B, CDH1, CDK2, CDK4, CDK6, CDKN1B, CDKN2A, CDKN2B, CEBPA, CHD1, CHEK2, CIC, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, CTNNB1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DIS3, DNMT3A, EBF1, EGFR, EGR1, EIF1AX, EP300, EPCAM, EPHA2, EPOR, ERBB2, ERBB3, ERBB4, ESR1, ETNK1, ETV6, EWSR1, EZH2, FAM46C, FAS, FAT1, FBXW7, FGF19, FGFR1, FGFR2, FGFR3, FLT1, FOXO1, FUBP1, GAB2, GATA2, GATA3, GNA11, GNA13, GNAI2, GNAQ, GNAS, GNB1, H3F3A, HIF1A, HIST1H1E, HNF1A, HRAS, ID3, IDH1, IDH2, IGF1R, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KLF2, KRAS, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K14, MAP3K9, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MET, MITF, MLH1, KMT2D, MPL, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NF1, NF2, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, PMS2, POLE, POT1, PPM1D, PRDM1, PRPS1, PTCH1, PTEN, PTPN11, RAC1, RAD21, RB1, REL, RET, RHEB, RHOA, RICTOR, RIPK1, RIT1, RNF43, ROS1, RPS15, RUNX1, S1PR2, SAMHD1, SETBP1, SETD2, SF3B1, SGK1, SH2B3, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SOCS1, SOX2, SPEN, SPOP, SRSF2, STAG2, STAT3, STAT5B, STAT6, STK11, TBL1XR1, TCF3, TERT, TET2, TGFBR1, TGFBR2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, TSC1, TSC2, U2AF1, UBR5, VHL, WT1, XPO1, ZFHX4, ZMYM3, and ZRSR2 genes is determined using next-generation sequencing (NGS) technology.
NexCourse® is a registered trademark of Genoptix, Inc.
Polymerase chain reaction (PCR) and subsequent fragment analysis of paired normal and tumor tissue is used to determine microsatellite instability (MSI). Results are reported as MSI-H (at least two markers are unstable) or MSS (less than two markers are unstable).
There are several key genes recurrently mutated in melanoma. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the BRAF, CD274, CDK4, HRAS, KIT, KRAS, NF1, and NRAS genes is determined using next-generation sequencing (NGS) technology.
CONTACT US
Genoptix, a NeoGenomics Company
2131 Faraday Ave
Carlsbad, CA 92008
Phone: +1.760.268.6200
Fax: +1.760.268.6201
Client Services
Phone: +1.800.755.1605
Fax: +1.888.755.1604
Email: clientservices@genoptix.com
Medical Director: Derek Lyle, MD
Recent News
NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
